Shanghai Junshi Biosciences Co Revenu Q/Q
Quel est le Revenu Q/Q de Shanghai Junshi Biosciences Co?
Le Revenu Q/Q de Shanghai Junshi Biosciences Co., Ltd. est -54.91%
Quelle est la définition de Revenu Q/Q?
La croissance trimestrielle du chiffre d'affaires, d'une année sur l'autre , correspond à l'augmentation du chiffre d'affaires d'une entreprise par rapport à la performance du trimestre correspondant d'un exercice précédent, exprimée en pourcentage.
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
Revenu Q/Q des entreprises dans Health Care secteur sur OTC par rapport à Shanghai Junshi Biosciences Co
Que fait Shanghai Junshi Biosciences Co?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Entreprises avec revenu q/q similaire à Shanghai Junshi Biosciences Co
- Zhangmen Education a Revenu Q/Q de -54.97%
- China Everbright Greentech a Revenu Q/Q de -54.97%
- China Properties Investment a Revenu Q/Q de -54.96%
- Pil Italica Lifestyle a Revenu Q/Q de -54.95%
- Dixon Technologies (India) a Revenu Q/Q de -54.93%
- LSL Property Services Plc a Revenu Q/Q de -54.93%
- Shanghai Junshi Biosciences Co a Revenu Q/Q de -54.91%
- ECSC plc a Revenu Q/Q de -54.90%
- H&R Block a Revenu Q/Q de -54.90%
- Codiak BioSciences a Revenu Q/Q de -54.88%
- e Tera SA a Revenu Q/Q de -54.87%
- Titagarh Wagons a Revenu Q/Q de -54.86%
- Lai Sun Garment (International) a Revenu Q/Q de -54.84%